ibandronic acid has been researched along with Calcinosis in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (77.78) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Åsberg, A; Bollerslev, J; Dahle, DO; Godang, K; Hartmann, A; Kile, H; Pasch, A; Smerud, KT | 1 |
Linhartova, K; Sterbakova, G; Vyskocil, V | 1 |
Omid, N; Price, PA; Than, TN; Williamson, MK | 1 |
Nguyen, TM; Price, PA; Than, TN; Williamson, MK | 1 |
Alexandersen, P; Bagger, YZ; Christiansen, C; Qin, G; Tankó, LB | 1 |
Price, PA; Roublick, AM; Williamson, MK | 1 |
De Broe, M; Ketteler, M; Persy, V | 1 |
Faus, SA; Price, PA; Williamson, MK | 1 |
Buckley, JR; Price, PA; Williamson, MK | 1 |
2 trial(s) available for ibandronic acid and Calcinosis
Article | Year |
---|---|
A rapid and sustained improvement of calcification propensity score (serum T
Topics: Bone Density Conservation Agents; Calcinosis; Diphosphonates; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Survival; Humans; Ibandronic Acid; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Norway; Prognosis; Propensity Score; Prospective Studies; Risk Factors | 2017 |
Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aortic Diseases; Bone Density; Bone Resorption; Calcinosis; Diphosphonates; Disease Progression; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Long-Term Care; Middle Aged; Osteoporosis, Postmenopausal | 2005 |
7 other study(ies) available for ibandronic acid and Calcinosis
Article | Year |
---|---|
Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease--a pilot retrospective study.
Topics: Aged; Alendronate; Aortic Valve Stenosis; Bone Density Conservation Agents; Calcinosis; Comorbidity; Diphosphonates; Disease Progression; Female; Hemodynamics; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Pilot Projects; Retrospective Studies | 2010 |
The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption.
Topics: Animals; Anthraquinones; Arteries; Bone Resorption; Calcinosis; Calcium; Chlorides; Diphosphonates; Drug Therapy, Combination; Ferric Compounds; Ibandronic Acid; Injections, Subcutaneous; Male; Phosphates; Rats; Rats, Sprague-Dawley; Skin; Staining and Labeling; Vitamin D | 2002 |
Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat.
Topics: alpha-Fetoproteins; Animals; Aorta, Abdominal; Aortic Diseases; Bone Resorption; Calcinosis; Diphosphonates; Glycoproteins; Ibandronic Acid; Male; Minerals; Osteoprotegerin; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Vitamin D | 2004 |
Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate.
Topics: alpha-Fetoproteins; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcinosis; Calcium-Binding Proteins; Diet, Protein-Restricted; Dietary Proteins; Diphosphonates; Extracellular Matrix Proteins; Ibandronic Acid; Kidney; Male; Matrix Gla Protein; Osteocalcin; Rats; Rats, Sprague-Dawley; Renal Artery; Uremia; Vascular Diseases | 2006 |
Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels?
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Calcinosis; Diphosphonates; Ibandronic Acid; Kidney; Kidney Failure, Chronic; Mice; Rats; Vascular Diseases | 2006 |
Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.
Topics: Alendronate; Animals; Aortic Diseases; Bone Resorption; Calcification, Physiologic; Calcinosis; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Male; Muscle, Smooth, Vascular; Osteoporosis; Rats; Rats, Sprague-Dawley; Vitamin D; Warfarin | 2001 |
The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats.
Topics: Animals; Calcinosis; Diphosphonates; Heart Valve Diseases; Ibandronic Acid; Kidney Diseases; Lung Diseases; Male; Rats; Rats, Sprague-Dawley; Vitamin D | 2001 |